List of Excipients in Branded Drug SIROLIMUS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	.ALPHA.-TOCOPHEROL ACETATE
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	CALCIUM SULFATE
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	CARNAUBA WAX
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	CELLULOSE, MICROCRYSTALLINE
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	FERRIC OXIDE YELLOW
Greenstone LLC	SIROLIMUS	sirolimus	59762-1001	GLYCERYL OLEATE

Generic Drugs Containing SIROLIMUS

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	sirolimus	0904-7147	.ALPHA.-TOCOPHEROL, DL-
Major Pharmaceuticals	sirolimus	0904-7147	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	sirolimus	0904-7147	CROSCARMELLOSE SODIUM
Major Pharmaceuticals	sirolimus	0904-7147	EDETATE DISODIUM
Major Pharmaceuticals	sirolimus	0904-7147	GLYCERYL DIBEHENATE
Major Pharmaceuticals	sirolimus	0904-7147	HYPROMELLOSE

What are the Most Frequently-Used Excipients in SIROLIMUS?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL
2	.ALPHA.-TOCOPHEROL ACETATE
8	.ALPHA.-TOCOPHEROL, DL-
6	ALCOHOL
3	ALPHA-TOCOPHEROL
2	ALPHA-TOCOPHEROL ACETATE

Excipient Strategy and Commercial Opportunities for Sirolimus

Last updated: February 25, 2026

What is the current excipient formulation for Sirolimus?

Sirolimus (rapamycin), an immunosuppressive agent used primarily in transplant rejection prevention and certain cancer therapies, is formulated with various excipients depending on the dosage form and manufacturer.

Common formulations include:

• Oral tablets and capsules
  • Hydrating agents like hydroxypropyl cellulose
  • Lipids such as medium-chain triglycerides (MCT)
  • Surfactants like polysorbate 80
• Injectable solutions
  • Polyethylene glycol (PEG)
  • Sodium chloride or other buffering agents
  • Solvents such as ethanol

Major formulations include products like Rapamune (Pfizer), which utilizes specific excipient combinations for bioavailability and stability.

How does excipient choice impact Sirolimus's bioavailability and stability?

Excipient selection influences:

• Bioavailability: Lipophilic excipients like MCT improve solubilization, enhancing absorption.
• Stability: Antioxidants such as ascorbyl palmitate prevent oxidation; buffering agents maintain pH.
• Shelf life: Proper stabilizers prevent degradation, extending product shelf life.

Pfizer's Rapamune capsule incorporates excipients that facilitate delayed absorption, optimizing pharmacokinetics.

What are the strategic opportunities in excipient innovation for Sirolimus?

1. Lipid-based formulations

Use of self-emulsifying drug delivery systems (SEDDS) can enhance oral bioavailability, especially in complex cases where patient-specific absorption is compromised.

2. Nanoparticle technology

Incorporation of Sirolimus into nanoparticles with biocompatible excipients like poly(lactic-co-glycolic acid) (PLGA) improves solubility and targeted delivery.

3. Stabilizer and antioxidant development

New excipients that further extend stability under varied storage conditions can reduce packaging and distribution costs.

4. Alternative excipients to reduce immunogenicity

Use of inert or less immunogenic excipients can reduce adverse reactions, broadening patient eligibility.

5. Patient-centric formulations

Development of liquid or chewable forms with excipients tailored for pediatric or geriatric patients opens new markets.

What are the regulatory considerations for excipient modifications in Sirolimus?

• Changes to excipient composition require submission of supplemental filings to agencies like FDA or EMA.
• Demonstration of bioequivalence is necessary for formulations aiming to replace existing products.
• Excipients used must meet pharmacopeial standards and have acceptable toxicity profiles.

What is the competitive landscape regarding excipient innovation?

Major pharmaceutical companies invest in:

• Improved lipid excipients for enhanced bioavailability.
• Novel stabilizers for extended shelf life.
• Specialized delivery systems (liposomes, nanoparticles).

Patents cover specific excipient combinations, making innovation both a strategic and legal challenge.

What commercial opportunities exist for excipient suppliers?

• Supplying high-purity lipids, surfactants, and stabilizers to generic and branded manufacturers.
• Developing proprietary excipient systems for enhanced Sirolimus formulations.
• Partnering for customized excipient solutions targeting unmet clinical needs.

Market projections estimate the global drug excipient market to reach USD 8.9 billion by 2026, growing annually at approximately 5.5% [1].

Key Takeaways

• The excipient profile of Sirolimus directly influences its bioavailability, stability, and shelf life.
• Innovation in lipid-based formulations, nanoparticles, and stabilizers offers avenues for improved therapies.
• Regulatory navigation is critical for excipient modifications, requiring detailed submissions.
• The competitive landscape favors proprietary formulations with optimized excipient systems.
• Excipient suppliers have opportunities to develop specialized and high-quality ingredients, driven by increasing demand.

FAQs

1. Can excipient changes alter Sirolimus’s efficacy?
Yes. Changes affecting bioavailability or stability can impact therapeutic efficacy and safety, necessitating regulatory approval.

2. Which excipients are most common in Sirolimus formulations?
Lipids (medium-chain triglycerides), surfactants (polysorbate 80), stabilizers (antioxidants like ascorbyl palmitate), and buffering agents are frequently used.

3. Are there patent restrictions on excipient formulations for Sirolimus?
Yes. Patents often cover specific excipient combinations, formulations, and delivery systems.

4. What is the future outlook for Sirolimus excipient innovation?
Focus areas include lipid-based delivery systems, nanoparticle formulations, and stability-enhancing excipients.

5. How do excipients impact the supply chain for Sirolimus products?
Excipients with strict quality standards and complex manufacturing requirements can create supply chain constraints or opportunities for specialized suppliers.

---

References

[1] MarketsandMarkets. (2022). Drug delivery system market by type, route of administration, and application: Global forecast to 2026.